Node Positive (1-3 nodes), HR pos, HER2-neg
- SWOG S1007: Rx PONDER Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Node Positive or High Risk Node Negative, HER2-Neg
CTSU B-49: Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
Stage II and III
- SWOG 1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
- CTSU E2108: Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
For more information, contact Cheryl Patz, RN, OCN, CCRC, at (360) 715-4133.